Original ResearchPublished 24 September 2026Integrative multi-omics characterization of KLRB1/CD161 in diffuse large B-cell lymphoma: associations with immune context, subtype biology, and therapeutic responseErwei Li · Yingying Tang · Yuanyuan Wanyan · Yu LiangFrontiers in Molecular Biosciencesdoi 10.3389/fmolb.2026.1903725
ReviewPublished 22 September 2026The impact of deep learning and omics data in transforming precision therapy for brain cancerSana Munquad · Anam Upadhyay · Asim Bikas DasFrontiers in Bioinformaticsdoi 10.3389/fbinf.2026.1811813
Mini ReviewPublished 15 September 2026Menopause-associated gut microbiome remodeling and pharmacomicrobiomics: emerging mechanisms influencing drug responseSusanne B. HagaFrontiers in Microbiomesdoi 10.3389/frmbi.2026.1953547
Brief Research ReportPublished 3 September 2026The circulating metatranscriptome in acute myeloid leukemia patients: an RNA-seq reanalysisAn Dinh Duy Nguyen · Roshan Kern · Tatiana Dombrovski · Thomas LaFramboiseFrontiers in Microbiomesdoi 10.3389/frmbi.2026.1903806
Mini ReviewPublished 20 March 2026Beyond mutations: personalising oncology via RNA-editingIvo Fierro-MontiFrontiers in RNA Researchdoi 10.3389/frnar.2026.1779364
ReviewPublished 9 February 2026The impact of epigenetics on tumor metabolism: Friend or foe in drug response?Serena Castelli · Melania Franchini · Luigi Ferraro · Nicolò MangravitiFrontiers in Epigenetics and Epigenomicsdoi 10.3389/freae.2026.1755829
Mini ReviewPublished 30 January 2026Precision anesthesia and pharmacogenomics: a scoping review of personalized drug responseSarina Nikzad · Ofelia Loani Elvir-Lazo · Robert WongFrontiers in Anesthesiologydoi 10.3389/fanes.2026.1727481
